With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...
lack of insurance and unemployment could reduce the national HIV incidence by 29% over 10 years. The mathematical model, a novel integration of machine learning, probability theory and simulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback